// App-Quantinova.ai

TPS221 : A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.

Researchers

Presenter

  • Debashis Sarker

Principal Investigators

  • Udai Banerji

  • Sarah Patricia Blagden

  • Natalie Cook

  • T.R. Jeffry Evans

  • Elizabeth Ruth Plummer

  • Marina Braun

  • Ann Cleverly

  • Nieves Diaz

  • Paul Jones

  • Ivan Matthews

  • Sophie Glatt

Medical Centers

  • Kings College London, London, United Kingdom

  • Drug Development Unit, The Institute of Cancer Research, London, United Kingdom

  • University of Oxford, Oxford, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • UCB Biosciences, Monheim Am Rhein, Germany

  • UCB Pharma, Slough, UK Slough United Kingdom

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Tipiracil and trifluridine

  • Adrucil injection

  • Fluorouracil

  • Trifluridine

  • Oxaliplatin

  • leucovorin

  • mFOLFOX6

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT04393298

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved